Culturing cells has always been an important tool for biological research and drug discovery. Although most studies are based on 2D (two-dimensional) cell cultures, 3D (three-dimensional) cell cultures better mimic in vivo conditions, making them one of the fastest-growing experimental approaches in life sciences. Read Medilink EM Member Aurelia Bioscience's blog...
Driving in the EU after Brexit – what you need to know
Although the UK formally left the EU on 31 January 2020, the Government has agreed to a transition period that is due to last until the end of 2020. This means businesses and motorists are not required to take immediate action as all EU laws and regulations continue to apply...
Unprecedented regulatory shift for Economic Operators
The latest whitepaper from Medilink EM Member, Maetrics, helps clarify the new requirements for Economic Operators as the May 26, 2020 Date of Application for EU Medical Device Regulation approaches February 2020 - Maetrics, a leading international life sciences regulatory and compliance consultancy, has launched a whitepaper explaining the new (and...
The antibiotic era is almost over. What next?
For more than 100 years antibiotics have saved countless lives all over the world from infections that previously resulted in death. Unfortunately, due to the mismanagement of antibiotic usage, antibiotic-resistant bacteria are becoming more prevalent. Infections that were once treatable with first-line antibiotics are now resistant to entire classes of...
Deadline set for the CBD food industry
The Food Standards Agency (FSA) has set the cannabidiol (CBD) industry a deadline of 31 March 2021 to submit novel food authorisation applications. After this point, all products which have not submitted a valid application will be removed from the market. Local authorities have also been advised that businesses should be able...
Where next for cannabis-based medicines?
There has been much talk recently about the possible benefits of medicines derived from cannabis plants. With public pressure on governments to relax legislation, and increasing enthusiasm for investors, how positive is the prospect for these products? In a series of two articles, Medilink EM Patron Mills and Reeve consider...
Quotient Sciences, University of Nottingham, AstraZeneca and Added Scientific Ltd receive MRC grant to advance 3D printing of solid dosage forms
The Faculty of Engineering and School of Pharmacy, at the University of Nottingham, are delighted to announce the receipt of an MRC Confidence in Concepts grant. The University of Nottingham is a Medilink EM Patron and works with Medilink EM to drive life science growth across the East Midlands. The...
Should the East Midlands be claiming more in R&D Tax Relief?
Only 2.15% of Small and Medium Enterprises (SMEs) in the East Midlands claimed R&D Tax Relief in Financial Years 2016/17 and 2017/18. Medilink EM Patron TBAT Innovation says that there should be 1000’s more making a claim. SMEs from the East Midlands made up just 6.6% of the total businesses...
What does Brexit mean for your intellectual property (IP) rights?
The United Kingdom has now formally left the European Union (EU). Medilink EM Patron AdamsonJones discusses what this means for Intellectual Property rights. European Patents Patent protection will be unaffected by Brexit as there is currently no European Union system for protecting patents and the United Kingdom will continue to...
GWAS – what can our genotype tell us?
The average difference between any two human genomes is small, probably less than 0.1%. These differences can include variations in individual nucleotides (SNPs) as well as insertions and deletions of single and multiple nucleotides, and larger variations, where sections of the genome are repeated (copy number variation). While relatively small,...